content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

BioTime, Inc. (BTX)

2.63
0.15
(6.05%)
Sep 11, 4:00PM EDT
content_middle

BioTime (NYSEMKT: BTX), a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies.

BTX’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis.

BTX also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products.

Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia.

BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Previous Close: 
2.83
Open: 
2.87
Bid: 
2.84
Ask: 
2.99
1yr Target Price: 
6.17
Day's Range: 
2.81 - 2.88
52wk Range: 
1.98 - 3.16
Volume: 
179025
Average Daily Volume: 
353887
Market Capitalization: 
333.69M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
126.88M
content_right

Pages